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High-grade ovarian serous papillary cancer (OSPC) and uterine serous papillary carcinoma (USPC) represent two histologically similar
malignancies characterised by markedly different biological behavior and response to chemotherapy. Understanding the molecular
basis of these differences may significantly refine differential diagnosis and management, and may lead to the development of novel,
more specific and more effective treatment modalities for OSPC and USPC. We used an oligonucleotide microarray with probe sets
complementary to 410000 human genes to determine whether patterns of gene expression may differentiate OSPC from USPC.
Hierarchical cluster analysis of gene expression in OSPC and USPC identified 116 genes that exhibited 4two-fold differences
(Po0.05) and that readily distinguished OSPC from USPC. Plasminogen activator inhibitor (PAI-2) was the most highly
overexpressed gene in OSPC when compared to USPC, while c-erbB2 was the most strikingly overexpressed gene in USPC when
compared to OSPC. Overexpression of the c-erbB2 gene and its expression product (i.e., HER-2/neu receptor) was validated by
quantitative RT–PCR as well as by flow cytometry on primary USPC and OSPC, respectively. Immunohistochemical staining of
serous tumour samples from which primary OSPC and USPC cultures were derived as well as from an independent set of 20 clinical
tissue samples (i.e., 10 OSPC and 10 USPC) further confirmed HER-2/neu as a novel molecular diagnostic and therapeutic marker for
USPC. Gene expression fingerprints have the potential to predict the anatomical site of tumour origin and readily identify the
biologically more aggressive USPC from OSPC. A therapeutic strategy targeting HER-2/neu may be beneficial in patients harbouring
chemotherapy-resistant USPC.
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Ovarian serous papillary cancer (OSPC) represents the most
common histological type of ovarian carcinoma, the fourth leading
cause of cancer-related death in women in the United States (Jemal
et al, 2003). Endometrial cancer is the most frequent cancer of the
female genital tract with endometrioid (type 1) and serous
papillary (type 2) being the most common cell types (Deligdisch
and Holinka, 1987; Jemal et al, 2003). Histologically indistinguish-
able to high-grade serous ovarian carcinoma (Carcangiu and
Chambers, 1992; Sherman et al, 1992), uterine serous papillary
cancer (USPC) has a propensity for early intraabdominal,
lymphatic and distant metastatic spread even at presentation
(Carcangiu and Chambers, 1992; Goff et al, 1994; Nicklin and
Copeland, 1996) and is characterised by a highly aggressive
biological behavior (Deligdisch and Holinka, 1987; Carcangiu and
Chambers, 1992; Sherman et al, 1992; Goff et al, 1994; Nicklin and
Copeland, 1996). Unlike OSPC, however, which is responsive to
first-line combined cisplatinum-based chemotherapy in 70–80%
of the cases (Kalil and McGuire, 2002), USPC is a chemotherapy-
resistant disease from outset, with responses to cytostatic
agents in the order of 20% and of short duration (Levenback
et al, 1992; Carcangiu and Chambers, 1995; Nicklin and Copeland,
1996).
Gene expression fingerprints representing large numbers of
genes have the potential to allow precise and accurate grouping of
tumours endowed with similar phenotype (Giordano et al, 2001;
Sorlie et al, 2001; Rosenwald et al, 2002; Zhan et al, 2002). Gene
microarrays may identify cancers endowed with a more aggressive
biologic behaviour (i.e., rapidly metastatic tumours) that are
unresponsive to standard adjuvant therapies and may thus allow
improved prediction of response and clinical outcome. Consistent
with this view, in large B-cell lymphomas and breast carcinomas,
gene expression profiles have been shown to identify patients who
are unlikely to be cured by conventional therapy (Sorlie et al, 2001;
Rosenwald et al, 2002). In ovarian carcinoma, cDNA microarray
technology has recently been used to identify numerous genes
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ydifferentially expressed in normal and tumour-derived ovarian
epithelial cells (Ismail et al, 2000; Hough et al, 2001; Welsh et al,
2001; Schwartz et al, 2002). Interestingly, several of the most
upregulated genes encode surface or secreted proteins, such as
Kop, SLPI and claudin-3, making these products attractive
candidate biomarkers (Ismail et al, 2000; Hough et al, 2001;
Welsh et al, 2001; Schwartz et al, 2002). In contrast, very little is
known about the possible genetic diversity between OSPC and
USPC, two histologically similar serous carcinomas characterised
by a dramatically different biological behavior and response to
chemotherapy.
In this study, oligonucleotide microarrays were used to profile
and compare gene expression patterns in 11 primary cultures of
OSPC and USPC. We report that mRNA fingerprints readily
distinguish the more biologically aggressive and chemotherapy
resistant USPC from OSPC. Of interest, OSPC2, a primary OSPC
with mixed clear cell features (a variant of ovarian cancer also
characterised with a particularly unfavourable prognosis), clus-
tered with USPC. Plasminogen activator inhibitor (PAI-2) was the
gene most highly upregulated in OSPC relative to USPC, while the
c-erbB2 gene product (HER-2/neu) was strikingly overexpressed in
USPC relative to OSPC and may therefore represent a novel
diagnostic and therapeutic marker for this highly aggressive subset
of endometrial tumours.
MATERIALS AND METHODS
Establishment of OSPC and USPC primary cell lines
In all, 11 primary serous papillary cell lines (six OSPC and five
USPC) were established after sterile processing of the tumour
samples from surgical biopsies as described for ovarian
and uterine carcinoma specimens (Santin et al, 2000, 2002a,b).
All tumour samples were obtained with appropriate consent
according to IRB guidelines. Tumours were staged according
to the FIGO operative staging system. Total abdominal
hysterectomy and regional lymph node sampling for invasive
USPC were performed in all cases. Radical tumour debulking,
including a total abdominal hysterectomy and omentectomy, was
performed in all ovarian carcinoma patients. No patient received
chemotherapy before surgical therapy. The patient characteristics
are described in Table 1. The epithelial nature and the purity of
USPC and OSPC cultures was verified by immunohistochemical
staining and flow cytometric analysis with antibodies against
cytokeratin as described (Ismail et al, 2000; Santin et al, 2000,
2002a,b). Only primary cultures which had at least 90% viability
and contained 499% tumour cells were used for total RNA
extraction.
RNA purification, microarray hybridisation and analysis
RNA purification, cDNA synthesis, cRNA preparation and
hybridisation to the Affymetrix Human U95Av2 GeneChip
microarray were performed according to the manufacturer’s
protocols and as reported (Zhan et al, 2002).
Data processing
All data used in our analyses were derived from Affymetrix 5.0
software. GeneChip 5.0 output files are given as a signal that
represents the difference between the intensities of the sequence-
specific perfect match probe set and the mismatch probe set, or as
a detection of present, marginal, or absent signals as determined
by the GeneChip 5.0 algorithm. Gene arrays were scaled to an
average signal of 1500 and then analysed independently. Signal
calls were transformed by the log base 2 and each sample was
normalised to give a mean of 0 and variance of 1.
Gene expression data analysis
Statistical analyses of the data were performed with the software
packages SPSS10.0. (SPSS, Chicago, IL, USA) and the significance
analysis of microarrays (SAM) method (Tusher et al, 2001). Genes
were selected for analysis based on detection and fold change. In
each comparison, genes having ‘present’ detection calls in more
than half of the samples in the overexpressed gene group were
retained for statistical analysis if they showed 4two-fold change
between groups. Retained genes were subjected to SAM to
establish a false discovery rate (FDR), then further filtered via
the Wilcoxon rank-sum (WRS) test at a¼0.05. The FDR obtained
from the initial SAM analysis was assumed to characterise genes
found significant via WRS.
Gene cluster/treeview
The hierarchical clustering of average-linkage method with the
centred correlation metric was used (Eisen et al, 1998). The
dendrogram was constructed with a subset of genes from 12588
probe sets present on the microarray, whose expression levels
vary the most among the 11 samples, and thus most informative.
For the hierarchical clustering shown in Figures 1 and 2, only
genes significantly expressed and whose average change in
expression level was at least two-fold were chosen. The expression
value of each selected gene was re-normalized to have a mean of
zero.
Quantitative real-time PCR
q-RT – PCR was performed with an ABI Prism 7000 Sequence
Analyzer using the manufacturer’s recommended protocol (Ap-
plied Biosystems, Foster City, CA, USA) to validate differential
expression of selected genes in samples from six representative
primary tumour cell lines (three OSPC and three USPC). Each
reaction was run in triplicate. The comparative threshold cycle
(CT) method was used for the calculation of amplification fold as
specified by the manufacturer. Briefly, 5mg of total RNA from each
sample was reverse transcribed using SuperScript II Rnase H
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). A value of
10ml of reverse-transcribed RNA samples (from 500ml of total
volume) was amplified by using the TaqMan Universal PCR Master
Mix (Applied Biosystems) to produce PCR products specific for
PAI-2 and c-erbB2. Primers specific for 18s ribosomal RNA and
empirically determined ratios of 18s competimers (Applied
Biosystems) were used to control for the amounts of cDNA
generated from each sample. Sequences for primers and probes are
available on request. Differences among OSPC and USPC in the q-
RT – PCR expression data were tested using the Kruskal–Wallis
Table 1 Characteristics of the patients
Patient Age Race Stage Chemotherapy regimen
USPC 1 66 Afro-American IV B TAX+CARB
USPC 2 77 White III C TAX+CARB
USPC 3 61 Afro-American III C TAX+CARB
USPC 4 62 Afro-American III C TAX+CARB
USPC 5 63 Afro-American III C TAX+CARB
OSPC 1 42 White III C TAX+CIS
OSPC 2 43 White III C TAX+CARB
OSPC 3 34 White III C TAX+CARB
OSPC 4 51 White III C TAX+CARB
OSPC 5 59 Afro-American III B TAX+CARB
OSPC 6 52 White III C TAX+CARB
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used to estimate the degree of association between the microarray
and q-RT – PCR data.
Flow cytometry
To validate microarray data on primary OSPC and USPC cell lines
at the protein level, HER-2/neu receptor expression was evaluated
by flow cytometry. The HER-2/neu MAb Herceptin (Genentech,
San Francisco, CA, USA) was used as the primary antibody. FITC-
conjugated goat anti-human F(ab)
2 immunoglobulin was used as a
secondary reagent (BioSource International, Camarillo, CA, USA).
Analysis was conducted with a FACScan, utilising Cell Quest
software (Becton Dickinson).
HER2/neu immunostaining of formalin-fixed tumour
tissues
To evaluate whether the differential HER2/Neu receptor expression
detected by flow cytometry on primary OSPC and USPC cell lines
was comparable to the expression of HER-2/neu receptor of
uncultured OSPC and USPC from which the primary cell lines were
derived, protein expression was evaluated by immunohistochem-
ical staining on formalin-fixed tumour tissue. In addition, to
further confirm transcriptional profiling results, the HER2/neu
marker was also evaluated by immunohistochemistry in a second
independent set of 20 clinical tissue samples (i.e., 10 OSPC and 10
USPC) obtained from patients harbouring advanced stage disease
(i.e., stages III and IV). Study blocks were selected after
histopathologic review by a surgical pathologist. The intensity of
staining was graded as 0 (staining not greater than negative
control), 1þ (light staining), 2þ (moderate staining) or 3þ
(heavy staining).
RESULTS
Gene expression profiles distinguish OSPC from USPC and
identify differentially expressed genes
Flash frozen biopsies from ovarian and uterine tumour tissue
are known to contain significant numbers of contaminant stromal
cells as well as a variety of host-derived immune cells (e. g.,
monocytes, dendritic cells, lymphocytes). Short-term primary
OSPC and USPC cell cultures, minimising the risk of a selection
bias inherent in any long-term in vitro growth, provide an
opportunity to study differential gene expression between
relatively pure populations of tumour cells. Comprehensive
gene expression profiles of six primary OSPC and five primary
USPC cell lines were generated using high-density oligonucleotide
arrays with 12588 probe sets, which in total interrogated
some 10000 genes. In total, 165 genes were differentially expressed
between OSPC and USPC (WRS test, Po0.05). Figure 1 shows
the cluster analysis performed on hybridisation intensity
values for 59 gene segments whose average difference in
expression level was at least two-fold. Two major branches on
the dendrogram were identified. All five USPC were grouped
together in the rightmost columns. Similarly, in the leftmost
columns five pure OSPC were found to cluster tightly together. Of
interest, OSPC2, a serous papillary tumour with mixed clear cell
features (i.e., a biologically aggressive variant of ovarian cancer
characterised by a poor prognosis) clustered on a sub-branch with
USPC (Figure 1). Figure 2 shows the cluster analysis on
hybridisation intensity values for each gene in 10 primary cultures
of OSPC and USPC showing a single type of differentiation. There
were 484 genes showing 4two-fold change along with ‘present’
detection calls in more than half the samples in the overexpressed
group. Of these, 316 were found significant by SAM, with a median
FDR of 17.4% and a 90th percentile FDR of 22.7%. Of the 484
aforementioned genes, 116 yielded Po0.05 via WRS, and all 116
were among the genes found significant by SAM. Thus, we can say
with 90% confidence that the FDR among genes found significant
via WRS is no higher than 22.7%. The new dendrogram shown in
Figure 2 depicts a marked separation in the expression profiles of
the two groups of serous papillary tumours. The tight clustering of
pure OSPC from USPC was driven by two distinct profiles of gene
expression. The first was represented by a group of 40 genes that
were highly expressed in OSPC and underexpressed in USPC
(Table 2). Many genes shown previously to be involved in ovarian
carcinogenesis are present on these lists, providing a degree of
validity to our array analysis. Included in this group of genes are
plasminogen activator inhibitor-2 (PAI-2), fibroblast growth factor
receptor-2 (FGFR2), glypican 1 (GPC1), lysophosphatidic acid
receptor (EDG2), phospholipase C (PLCL2), glucose-6-phosphate
dehydrogenase (G6PD) and insulin receptor (IGF1) (Table 2). The
second profile was represented by 76 genes that were highly
expressed in USPC and underexpressed in OSPC (Table 3).
Included in this group of genes are epidermal growth factor type
2 receptor (c-erbB2), inhibin (INHBB), multiple endocrine neopla-
sia I (MEN1), growth factor receptor-bound protein 7 (GRB7),
BCL2, E-cadherin (CDH1) and syndecan (SDC2) (Table 3).
Importantly, c-erbB2 gene was the most highly differentially
expressed gene in USPC when compared to OSPC (Table 3,
Table 4, Figure 2). OSPC2, the only serous tumour with mixed clear
cell histology evaluated in our series, was also found to highly
overexpress c-erbB2 (data not shown).
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Figure 1 Molecular profile of 11 primary OSPC and USPC cell lines.
Hierarchical clustering of 59 genes with differential expression between six
OSPC and five USPC groups (Po0.05) using a two-fold threshold. The
cluster is colour coded using red for upregulation, green for downregulation
and black for median expression. Agglomerative clustering of genes was
illustrated with dendrograms. The symbol for each gene corresponding to
the oligonucleotide spotted on the array is shown.
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We used q-RT – PCR assays to validate the microarray data. The
two most highly differentially expressed genes between OSPC and
USPC (i.e., PAI-2 and c-erbB2) were selected for q-RT – PCR
analysis. A comparison of the microarray and q-RT – PCR data for
these genes is shown in Figure 3. Expression differences between
tumour types for PAI-2 (P¼0.009) and c-erbB2 (P¼0.02), were
readily apparent (Tables 2 and 3). Moreover, for both genes tested,
the q-RT – PCR data were highly correlated to the microarray data
(Po0.001) (r¼0.91 and 0.71, respectively), as estimated from the 6
samples (i.e., three OSPC and three USPC) included in both the q-
RT – PCR and microarray experiments. The q-RT – PCR data
mirror the microarray data, both qualitatively and quantitatively,
and suggest that most array probe sets are likely to accurately
measure the levels of the intended transcript within a complex
mixture of transcripts.
HER-2/neu expression
We evaluated HER-2/neu expression by flow cytometry on six
primary serous papillary cell lines (three OSPC and three USPC).
As positive and negative controls, breast cancer cell lines known to
overexpress HER-2/neu (BT-474 and SK-BR-3, American Type
Culture Collection), and Epstein – Barr virus-transformed
lymphoblastoid cell lines (LCL) established from the same USPC
and OSPC patients were also studied. High HER-2/neu receptor
expression was found on all three primary USPC cell lines tested
(100% positive cells for all three USPC), with mean fluorescence
intensity (MFI) ranging from 94 to 140 (Figure 4). In contrast,
primary OSPC cell lines were found to express significantly lower
levels of HER-2/neu (average MFI was 10-fold lower) than the
USPC cells (Po0.001) (Figure 4). These results show that high
expression of the c-erbB2 gene product by USPC correlates tightly
with high protein expression by the tumour cells. Autologous LCL
were consistently negative for HER-2/neu expression, while breast
cancer cell lines expressed high levels of HER-2/neu (data not
shown).
Immunohistochemical analysis of HER2/neu expression
Formalin-fixed tumour tissue blocks from six primary surgical
specimens were tested for HER-2/neu expression. Heavy staining
for HER-2/neu protein expression (i.e., score 3þ) was noted in all
three USPC specimens that also overexpressed the c-erbB2 gene
product by microarray and flow cytometry, respectively (Figure 5).
In contrast, negative or low (i.e., score 0 or 1þ) staining was
found in all three representative OSPC samples (Figure 5).
Similarly, when formalin-fixed tumour tissue blocks from 20
independent surgical specimens (i.e., 10 OSPC vs 10 USPC) were
tested for HER-2/neu expression, a moderate to heavy staining was
found in 70% of USPC (i.e., 70% score 2þ and 3þ, 30% score
1þ) vs 10% of OSPC (i.e., 10% score 2þ and 90% score 0 to 1þ)
(P¼0.0002 USPC vs OSPC by student’s t-test).
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Figure 2 Molecular profile of primary OSPC and USPC cell lines. Hierarchical clustering of 116 genes with differential expression between five OSPC and
five USPC groups (Po0.05) using a two-fold threshold. The cluster is colour coded using red for upregulation, green for downregulation and black for median
expression. Agglomerative clustering of genes was illustrated with dendrograms. The symbol for each gene corresponding to the oligonucleotide spotted on
the array is shown. USPC upregulated genes are shown in red ink while OSPC upregulated genes are shown in blue ink.
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yDISCUSSION
High-throughput comprehensive technologies for assaying gene
expression, such as high-density oligonucleotide and cDNA
microarrays, may offer the potential to identify clinically relevant
subsets of tumours difficult to distinguish by conventional
histopathological assessment (Giordano et al, 2001; Rosenwald
et al, 2002; Schwartz et al, 2002). This report represents the first
communication of an investigation involving the genome-wide
examination of differences in gene expression between serous
papillary ovarian cancer (OSPC) and uterine serous papillary
carcinoma (USPC), two histologically indistinguishable gynaeco-
logic tumours characterised by a dramatically different biologic
behavior and response to chemotherapy.
Advanced and/or metastatic serous papillary gynaecologic
tumours, regardless of their ovarian or uterine origin, are currently
treated with a combined cisplatinum-based chemotherapy. How-
ever, given that: (1) USPC likely arise from metaplastic Mullerian
epithelium, while OSPC likely derive from the ovarian surface
epithelium, and (2) a dramatic difference in response to standard
chemotherapy regimens is commonly reported among these
histologically indistinguishable serous carcinomas (Levenback
et al, 1992; Sherman et al, 1992; Carcangiu and Chambers, 1995;
Nicklin and Copeland, 1996; Kalil and McGuire 2002), a significant
diversity in gene expression among these tumours is probable. In
agreement with this view, all five USPC patients evaluated in this
study either developed progressive disease during chemotherapy
or recurred within 6 months from the end of treatment. In
contrast, four out of five of the OSPC patients responded
completely to standard adjuvant chemotherapy treatment. In this
study, we have used short-term primary OSPC and USPC cultures
(to minimise the risk of a selection bias inherent in any long-term
in vitro growth) to study differential gene expression in highly
enriched populations of epithelial tumour cells. Strikingly, we
found that hierarchical clustering of the samples and gene
expression levels within the samples led to the unambiguous
separation of OSPC from USPC. We detected 116 genes
differentially expressed between OSPC and USPC whose average
change in expression level between the two groups was at least
two-fold. Of the 116 genes that yielded Po0.05 via WRS, all 116
were among the genes found significant by SAM. Our study offers
therefore the first persuasive support that the dramatically
different biologic behaviour and response to treatment commonly
reported in OSPC compared to USPC may be dictated by a
profound genetic diversity among these histological indistinguish-
able serous neoplasms. It is therefore likely that a molecular
classification based on gene expression profiles may thus
potentially identify gynaecologic serous tumours associated with
aggressive behaviour and poor prognosis and should allow
therapeutic approaches to be better tailored to the biologic and
Table 2 Upregulated genes expressed at least two fold higher in OSPC compared with USPC
Probe set name Gene symbol Map location p of WRS Ratio Ov/Ut
37185_at SERPINB2 18q21.3 0.00902344 21.2101742
40478_at DJ971N18.2 20p12 0.0162936 7.391447995
38837_at DJ971N18.2 20p12 0.047201768 6.933671714
34439_at AIM2 1q22 0.00902344 6.689727463
36073_at NDN 15q11.2-q12 0.028280124 6.460327167
859_at CYP1B1 2p21 0.047201768 4.642443935
40387_at EDG2 9q32 0.047201768 4.612620508
1669_at WNT5A 3p21-p14 0.028280124 4.35214472
1363_at FGFR2 10q26 0.0162936 3.958060853
1143_s_at 0.028280124 3.948020982
37816_at C5 9q32-q34 0.0162936 3.945622621
40071_at CYP1B1 2p21 0.047201768 3.826875845
38294_at HOXD4 2q31-q37 0.028280124 3.804399853
33162_at INSR 19p13.3-p13.2 0.047201768 3.772
34853_at FLRT2 14q24-q32 0.047201768 3.471204819
40395_at PLXNA2 1q32.1 0.028280124 3.371729137
39805_at ABCB6 2q36 0.047201768 3.369062784
41796_at PLCL2 3p24.3 0.00902344 3.280007364
1403_s_at SCYA5 17q11.2-q12 0.047201768 3.158368265
33929_at GPC1 2q35-q37 0.028280124 3.15594993
39566_at CHRNA7 15q14 0.047201768 3.14079953
34354_at FGFR2 10q26 0.047201768 2.928346342
444_g_at HOXD4 2q31-q37 0.047201768 2.892672123
38042_at G6PD Xq28 0.047201768 2.813117012
36077_at RABL4 22q13.1 0.028280124 2.720984156
36453_at KIAA0711 8p23.3 0.047201768 2.688792044
32668_at SSBP2 5q14.1 0.047201768 2.663148439
32610_at RIL 5q31.1 0.047201768 2.55031145
514_at CBLB 3q13.12 0.028280124 2.511893491
40112_at IDH3B 20p13 0.028280124 2.294973901
38271_at HDAC4 2q37.2 0.028280124 2.245891142
1325_at MADH1 4q28 0.047201768 2.228503651
32381_at RORB 9q22 0.028280124 2.205852674
32800_at RXRA 9q34.3 0.047201768 2.168594631
36312_at SERPINB8 18q21.3 0.047201768 2.110497544
40142_at DDX24 14q32 0.0162936 2.109997452
33227_at IL10RB 21q22.11 0.047201768 2.082986437
32529_at CKAP4 12q23.3 0.047201768 2.04858844
37280_at MADH1 4q28 0.028280124 2.044781456
39709_at SEPW1 19q13.3 0.028280124 2.017195806
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ygenetic characteristic of each serous tumour type. These novel
findings have thus the potential to significantly refine diagnosis
and possibly alter management of these cancer patients. Of
interest, OSPC2, the only OSPC with mixed clear cell features
included in our analysis, clustered with USPC. These data are
congruent with a recent report that clear cell ovarian tumours
present a distinctive molecular signature from pure high-grade
OSPC (Schwartz et al, 2002). Thus, our findings add to previous
knowledge showing that clear cell tumours, a variant of ovarian
cancer with a particularly unfavourable prognosis, express
a molecular signature closer to that of the more aggressive
USPC.
A sizeable number of genes differentially expressed in OSPC
compared with USPC have been identified through our analysis.
Some of these may prove to be useful diagnostic and therapeutic
markers for these histologically similar diseases. For example,
elevated serum levels of lysophosphatidic acid (LPA) are found in
more than 90% of ovarian cancer patients and the level of LPA in
plasma has been proposed as a potential biomarker for this disease
(Budnik and Mukhopadhyay, 2002). In addition, LPA signalling
may have a role in the progression of ovarian cancer cells through
stimulation of cellular proliferation, enhanced cellular survival and
suppression of apoptosis (Contos et al, 2000). It seems therefore
likely that the higher LPA receptor expression found in OSPC
relative to USPC may represent a distinctive marker that plays a
role in transduction of growth-promoting signals from high local
concentrations of LPA (Contos et al, 2000; Budnik and Mukho-
padhyay, 2002). Consistent with this view, phospholipase C,
another gene that is differentially overexpressed in OSPC relative
to USPC has been previously reported to contribute to LPA
production in ovarian cancer cells (Budnik and Mukhopadhyay,
2002).
Several reports have shown that plasminogen activator inhibi-
tor-2 (PAI-2), a protein capable of inhibiting invasion (Andreasen
et al, 2000), may represent a molecular biomarker for several
human tumours including ovarian carcinomas. Consistent with
our findings, however, overexpression of PAI-2 in epithelial
ovarian cancer has been previously identified as a favourable
prognostic factor (Chambers et al, 1997). Indeed, high PAI-2
expression in invasive ovarian tumours seem to be limited to a
group of OSPC patients which experience a more prolonged
disease free and overall survival (Chambers et al, 1997). These data
are therefore consistent with the view that high expression of PAI-
2 in OSPC compared to USPC may be a marker indicating a
biologically less aggressive disease.
Membrane-associated heparan sulphate proteoglycans are
thought to play important roles in many aspects of cell behaviour,
including cell – cell and cell – extracellular matrix adhesion and
growth factor signalling (David, 1993). Two families of polypep-
tides appear to carry the majority of heparan sulphate on
mammalian cells: glypicans, which are attached to the plasma
membrane via glycosylphosphatidylinositol (GPI) anchors, and
syndecans, which are transmembrane proteins (David, 1993).
Table 3 Upregulated genes expressed at least two-fold higher in USPC
compared with OSPC
Probe set
name Gene symbol
Map
location p of WRS Ratio Ut/Ov
1802_s_at ERBB2 17q11.2-q12 0.028280124 17.39166248
39470_at 0.00902344 14.13960749
41470_at PROML1 4p15.33 0.00902344 11.00274366
32521_at SFRP1 8p12-p11.1 0.047201768 10.49619245
33218_at ERBB2 17q11.2-q12 0.0162936 9.009761458
41354_at STC1 8p21-p11.2 0.0162936 7.780569927
41700_at F2R 5q13 0.028280124 7.299013748
38207_at MEN1 11q13 0.028280124 6.578419265
36254_at TAC1 7q21-q22 0.047201768 6.292979547
38268_at SLC1A1 9p24 0.0162936 5.506571087
33576_at KIAA0918 13q31.1 0.0162936 5.478319783
37883_i_at AF038169 2q22.1 0.0162936 5.06566416
35704_at HRASLS3 11q13.1 0.028280124 4.596441783
38267_at SLC1A1 9p24 0.028280124 4.488128886
41376_i_at UGT2B7 4q13 0.047201768 4.418941048
828_at PTGER2 14q22 0.028280124 4.338041431
39506_at 0.028280124 4.313685637
1680_at GRB7 17q12 0.047201768 4.262623744
38545_at INHBB 2cen-q13 0.028280124 4.198823428
40679_at SLC6A12 12p13 0.047201768 3.956969879
35912_at MUC4 3q29 0.028280124 3.94095027
39966_at CSPG5 3p21.3 0.047201768 3.918103678
32027_at PDZK1 1q21 0.047201768 3.91484375
31732_at RLN2 9p24.1 0.0162936 3.913095715
36202_at PKIA 8q21.11 0.047201768 3.89984472
37978_at QPRT 16q13 0.0162936 3.845374532
994_at PTPRM 18p11.2 0.047201768 3.812843137
37208_at PSPHL 7q11.2 0.028280124 3.654717567
37884_f_at AF038169 2q22.1 0.028280124 3.593346825
995_g_at PTPRM 18p11.2 0.028280124 3.555706062
35985_at AKAP2 9q31-q33 0.028280124 3.319448607
32963_s_at RAGD 6q15-q16 0.00902344 3.280777993
33358_at KIAA1157 12q13.13 0.0162936 3.250881457
311_s_at 0.0162936 3.138465417
35674_at PADI2 1p35.2-
p35.1
0.047201768 3.100307522
2021_s_at CCNE1 19q12 0.028280124 3.081090355
32893_s_at GGT2 22q11.23 0.047201768 3.055014721
36869_at PAX8 2q12-q14 0.047201768 3.050015496
36508_at GPC4 Xq26.1 0.0162936 2.887073572
39901_at MYO7A 11q13.5 0.028280124 2.885983264
35148_at TJP3 19p13.3 0.028280124 2.879832572
31892_at PTPRM 18p11.2 0.047201768 2.844557651
36990_at UCHL1 4p14 0.0162936 2.833524684
37209_g_at PSPHL 7q11.2 0.047201768 2.780479031
38168_at INPP4B 4q31.1 0.00902344 2.645321215
36943_r_at PLAGL1 6q24-q25 0.0162936 2.57527834
37258_at TMEFF1 9q31 0.047201768 2.55946924
36985_at IDI1 10p15.3 0.047201768 2.538587569
39075_at NEU1 6p21.3 0.0162936 2.521110072
40488_at DMD Xp21.2 0.00902344 2.507697552
39332_at TUBB 6p21.3 0.047201768 2.504487188
39757_at SDC2 8q22-q23 0.047201768 2.452025072
933_f_at ZNF91 19p13.1-p12 0.028280124 2.445525292
37210_at INA 10q25.1 0.047201768 2.387532735
1860_at TP53BP2 1q42.1 0.0162936 2.356857655
37869_at ELKS 12p13.3 0.028280124 2.356300578
33878_at FLJ13612 2q36.1 0.0162936 2.319659881
35143_at DKFZP566A1524 0.047201768 2.312331476
38997_at SLC25A1 22q11.21 0.00902344 2.304275318
40077_at ACO1 9p22-p13 0.028280124 2.297124855
36261_at LOC51760 16p13.13 0.028280124 2.252602915
39436_at BNIP3L 8p21 0.047201768 2.236567978
977_s_at CDH1 16q22.1 0.00902344 2.212331718
36175_s_at HIVEP2 6q23-q24 0.047201768 2.206300362
41269_r_at API5 11p12-q12 0.0162936 2.189353711
1837_at 0.047201768 2.180124558
1818_at 0.047201768 2.177494716
366_s_at NEK2 1q32.2-q41 0.047201768 2.157771457
40900_at 0.028280124 2.151464435
40194_at 0.028280124 2.133081444
41172_at ARSDR1 14q23.3 0.0162936 2.113388456
37999_at CPO 3q12 0.028280124 2.100322069
35978_at PRRG1 Xp21.1 0.028280124 2.05552932
121_at PAX8 2q12-q14 0.028280124 2.028946437
41715_at PIK3C2B 1q32 0.00902344 2.024856688
41644_at KIAA0790 6q24.3 0.047201768 2.004743183
Table 3 (Continued)
Probe set
name Gene symbol
Map
location p of WRS Ratio Ut/Ov
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Figure 3 Quantitative RT – PCR and microarray expression analysis of PAI-2 (SERPINB2) and c-erbB2 (ERBB2) selected genes differentially expressed
between OSPC and USPC.
Table 4 Differentially expressed genes in USPC and OSPC ranked by significance analysis of microarrays (SAM)
Order Probeset Gene ID Score (d) Numerator (r) Denominator (s+s0) Fold change q-value (%)
1 39470_at 39470_at 2.5193455 3.596293949 1.427471523 13.48750 5.9170776
2 41470_at PROM1 2.1986583 3.825972532 1.740139698 10.60748 5.9170776
3 41354_at STC1 2.0805893 2.751729734 1.322572262 7.74726 5.9170776
4 38207_at 38207_at 2.0726086 3.311991516 1.597982165 6.51440 5.9170776
5 1802_s_at ERBB2 1.9669529 3.492165691 1.775419064 17.65875 5.9170776
6 39506_at 39506_at 1.9191495 3.359977858 1.750763964 4.15946 5.9170776
7 33218_at ERBB2 1.8831385 2.592838393 1.376870795 9.12831 5.9170776
8 37978_at QPRT 1.8508847 2.471411028 1.335259314 3.80801 5.9170776
9 35912_at MUC4 1.8095618 2.831603133 1.564800451 3.85299 5.9170776
10 41376_i_at UGT2B7 1.8010151 3.20113721 1.777407186 4.20987 5.9170776
11 37208_at PSPHL 1.784549 3.621295275 2.029249576 3.44056 5.9170776
12 38545_at INHBB 1.7806599 3.920162398 2.201522201 4.16889 5.9170776
13 33576_at KIAA0918 1.7555623 2.180726438 1.242181175 5.31405 5.9170776
14 32521_at SFRP1 1.7432391 2.824069509 1.620012708 10.60682 5.9170776
15 35704_at HRASLS3 1.7261492 2.548006268 1.476121705 4.49637 5.9170776
16 33358_at ARHCL1 1.6665422 1.95881684 1.175377897 3.16918 5.9170776
17 31732_at RLN2 1.6347725 2.459163154 1.50428461 3.67860 5.9170776
18 38267_at SLC1A1 1.6306308 2.219928654 1.361392538 4.39416 5.9170776
19 37883_i_at AF038169 1.6147363 2.219700503 1.374652015 4.98971 5.9170776
20 32963_s_at RRAGD 1.6121619 1.626523265 1.008908118 3.26944 5.9170776
21 994_at PTPRM 1.6097261 2.784507191 1.729801847 3.63111 5.9170776
22 995_g_at PTPRM 1.6088285 2.897830612 1.801205444 3.40453 5.9170776
23 311_s_at 311_s_at 1.5938406 4.139143468 2.596961926 3.01704 5.9170776
24 38268_at SLC1A1 1.5621501 2.110626126 1.351103322 5.35166 5.9170776
25 31892_at PTPRM 1.5119824 3.112003216 2.058227135 2.74704 5.9170776
26 35148_at TJP3 1.510845 1.998741079 1.322929233 2.73928 5.9170776
27 41700_at F2R 1.5014465 2.195953257 1.462558397 7.18646 5.9170776
28 35674_at PADI2 1.479696 2.264084328 1.53010105 3.01842 5.9170776
29 1680_at GRB7 1.4698173 2.027019267 1.379096066 4.25537 5.9170776
30 37209_g_at PSPHL 1.4664685 1.930835879 1.316656891 2.66282 5.9170776
31 39966_at CSPG5 1.4455697 1.818363955 1.257887393 3.93459 5.9170776
32 36869_at PAX8 1.441286 2.813586886 1.95213647 2.99423 5.9170776
33 36202_at PKIA 1.4322379 2.002737974 1.398327765 3.74274 5.9170776
34 828_at PTGER2 1.4285229 1.890660776 1.32350749 4.10149 5.9170776
35 39075_at NEU1 1.4246097 1.46915449 1.031268071 2.50012 5.9170776
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y36 36990_at UCHL1 1.4234749 1.966718653 1.381632101 2.81907 5.9170776
37 36943_r_at PLAGL1 1.4016117 1.503433722 1.072646422 2.57234 5.9170776
38 40488_at DMD 1.3944472 1.630344124 1.16916874 2.42639 5.9170776
39 35985_at PALM2 1.3805351 2.00686626 1.4536872 3.22031 5.9170776
40 36254_at TAC1 1.3634058 2.750616522 2.017459875 6.36232 5.9170776
41 37869_at ELKS 1.3454118 1.248133462 0.927696233 2.33294 5.9170776
42 2021_s_at CCNE1 1.3294844 1.454719587 1.094198324 3.06396 5.9170776
43 33878_at FLJ13612 1.3274937 1.237854188 0.932474615 2.29949 5.9170776
44 39757_at SDC2 1.3043638 2.072350471 1.588782604 2.35737 5.9170776
45 36508_at GPC4 1.2991039 1.843342415 1.41893382 2.86605 5.9170776
46 933_f_at ZNF91 1.2741536 1.376374281 1.080226336 2.37962 5.9170776
47 41269_r_at API5 1.2739465 1.209800113 0.949647539 2.16666 5.9170776
48 40679_at SLC6A12 1.2660176 2.282007655 1.802508675 3.78353 5.9170776
49 38168_at INPP4B 1.2480709 1.359180414 1.089025041 2.54847 5.9170776
50 1860_at TP53BP2 1.2409357 1.215816901 0.979758188 2.35894 5.9170776
51 38997_at SLC25A1 1.2115515 1.434841782 1.184301064 2.27730 5.9170776
52 36261_at LOC51760 1.2106872 1.239580344 1.023865052 2.21646 5.9170776
53 37258_at TMEFF1 1.1973963 1.515221127 1.265429912 2.66426 5.9170776
54 37884_f_at AF038169 1.1701381 1.429952351 1.222037264 3.55995 5.9170776
55 39332_at MGC8685 1.1504101 1.560522625 1.356492456 2.45317 5.9170776
56 40077_at ACO1 1.1452896 1.324530845 1.15650301 2.29132 5.9170776
57 40194_at GTF2H2 1.1312711 1.17700447 1.040426546 2.11918 5.9170776
58 36985_at IDI1 1.1292005 1.378736024 1.220984217 2.55491 5.9170776
59 121_at PAX8 1.1201623 1.208458366 1.078824359 2.03114 5.9170776
60 977_s_at CDH1 1.1193705 2.699730529 2.411829333 2.20046 5.9170776
61 35143_at DKFZP566A1524 1.1183384 1.620344382 1.44888559 2.22206 5.9170776
62 37999_at CPO 1.1064994 1.06722326 0.964504126 2.06986 5.9170776
63 37210_at INA 1.1044125 1.281004592 1.159896882 2.40281 5.9170776
64 36175_s_at HIVEP2 1.0992289 1.174149577 1.068157485 2.19097 5.9170776
65 366_s_at NEK2 1.0763152 1.152375048 1.070666856 2.16698 5.9170776
66 32893_s_at GGT2 1.0751984 1.434104513 1.33380457 2.99540 5.9170776
67 41172_at RDH11 1.0679325 1.000763289 0.937103522 2.07342 5.9170776
68 35978_at PRRG1 1.0611643 1.103335239 1.039740243 2.04432 5.9170776
69 41715_at PIK3C2B 1.0489539 0.921860026 0.878837519 2.00231 5.9170776
70 39901_at EDIL3 1.0487582 1.199399171 1.143637468 2.81306 5.9170776
71 40900_at MYH10 1.033065 0.971734516 0.940632521 2.13908 6.1516929
72 39436_at BNIP3L 1.0248207 1.021584326 0.996841974 2.23030 6.1516929
73 32027_at PDZK1 1.0234011 1.294822852 1.265215452 3.74641 6.1516929
74 1818_at 1818_at 1.0226221 1.159537838 1.13388698 2.17253 6.1516929
75 41644_at SASH1 1.0075712 0.944905271 0.937804973 1.98700 6.2373918
76 1837_at 1837_at 0.8980795 1.048441576 1.167426238 2.15603 7.6204787
1 37185_at SERPINB2  2.712078  4.21769782 1.555153568 0.04432 5.9170776
2 34439_at AIM2  1.887056  2.3302995 1.234886275 0.14663 17.36191
3 33162_at INSR  1.7303429  2.66873302 1.542314531 0.26385 17.36191
4 40478_at DJ971N18.2  1.7156271  2.71817086 1.584359902 0.13539 17.36191
5 41796_at PLCL2  1.6656048  1.85109255 1.111363586 0.30311 17.36191
6 37816_at C5  1.5809083  2.31648603 1.465288041 0.24600 17.36191
7 859_at CYP1B1  1.5772674  3.24419453 2.056844985 0.20802 17.36191
8 40071_at CYP1B1  1.5585486  3.21119542 2.060375537 0.25050 17.36191
9 39566_at CHRNA7  1.5536961  2.40918109 1.550612809 0.31177 17.36191
10 36073_at NDN  1.4829481  3.50636378 2.364454837 0.14949 17.36191
11 38837_at DJ971N18.2  1.4796673  2.14671946 1.450812223 0.14290 17.36191
12 36077_at RABL4  1.4523961  1.96257543 1.351267383 0.36574 17.36191
13 40395_at PLXNA2  1.4373891  1.79826591 1.251064131 0.29518 17.36191
14 1669_at WNT5A  1.4102572  2.6444399 1.875147235 0.22963 17.36191
15 40387_at EDG2  1.3772565  2.25220008 1.635280028 0.22311 17.36191
16 39805_at ABCB6  1.3495984  2.0539729 1.521914154 0.30094 17.36191
17 32668_at SSBP2  1.305583  1.39323342 1.067135083 0.38204 17.36191
18 38294_at HOXD4  1.3021769  1.80385782 1.385263285 0.26382 17.36191
19 33929_at GPC1  1.2952699  1.49713601 1.155848702 0.32097 17.36191
20 444_g_at 444_g_at  1.2845736  1.70421346 1.326676407 0.34439 17.36191
21 1363_at FGFR2  1.2806909  1.57525259 1.230002183 0.24473 17.36191
22 40142_at DDX24  1.2701961  1.27558267 1.004240756 0.46178 17.36191
23 1143_s_at 1143_s_at  1.2593487  1.61800179 1.284792503 0.24502 17.36191
24 36453_at KIAA0711  1.229961  1.94610499 1.582249319 0.36118 17.36191
25 514_at CBLB  1.2010635  1.19235629 0.992750384 0.39810 17.36191
26 34853_at FLRT2  1.2008015  1.40750914 1.172141399 0.29102 17.36191
27 40112_at IDH3B  1.1932078  1.31001149 1.097890455 0.43852 17.36191
28 38271_at MGC16025  1.1909435  1.56930168 1.31769611 0.44320 17.36191
29 32381_at RORB  1.1900513  1.68115724 1.412676329 0.44795 17.36191
30 39709_at SEPW1  1.1672019  1.17314959 1.005095698 0.49329 17.36191
Table 4 (Continued)
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yConvincing evidence has recently been provided that glypican-1
can interact with FGF-2 and stimulate signalling of the FGF
receptor (Steinfeld et al, 1996). Importantly, high glypican-1 and
FGF receptor 2 gene expression were found differentially expressed
in OSPC when compared to USPC, while syndecan-2 gene
expression was significantly higher in USPC when compared
USPC. These data therefore support a major difference in the
expression of heparan sulphate proteoglycans between these two
subsets of histologically indistinguishable serous tumours.
Furthermore, because bFGF is produced by OSPC and can bind
to FGF receptor 2 expressed on these tumours (Steinfeld et al,
1996), it is likely that the combined overexpression of glypicans
and FGF receptor 2 genes found in OSPC may represent a common
molecular abnormality with important functional consequences
for the progression of OSPC.
Insulin receptor has been previously reported overexpressed on
OSPC and to be able to mediate a proliferative response in ovarian
cancer cells (Kalli et al, 2002). In our study, consistent with
previous reports, OSPC were found to differentially overexpress
the insulin receptor gene when compared to USPC. These results
therefore support a role for insulin receptor in the growth and
regulation of OSPC, but not in USPC.
Unlike OSPC, there have been remarkably few studies aimed at
identifying molecular markers characteristic of USPC. Because of
the common poor response to standard salvage treatment
modalities for advanced or recurrent USPC, the identification of
a number of USPC specific markers may lay the groundwork for
future studies testing some of these biomarkers for clinical utility
in the treatment of these highly aggressive and intrinsically
chemotherapy resistant tumours. Of great interest at this regard, c-
erbB2 gene was found to be the most highly differentially
expressed gene in USPC with over 17-fold upregulation compared
with OSPC. Furthermore, the growth factor receptor-bound
protein 7 (GRB7), a gene tightly linked to c-erbB2 and previously
reported coamplified and coexpressed with this gene in several
cancer types (Janes et al, 1997) was also highly differentially
expressed in USPC compared to OSPC. The striking overexpres-
sion of the c-erbB2 gene as well as of its gene expression product
31 38042_at G6PD  1.1666541  1.3074933 1.12072066 0.35407 17.36191
32 32610_at RIL  1.1500988  1.87581032 1.630999328 0.38759 17.36191
33 1325_at MADH1  1.1063114  1.23201185 1.113621238 0.44054 17.36191
34 32800_at RXRA  1.0647524  1.19695561 1.124163351 0.46285 17.36191
35 34354_at FGFR2  1.0353338  1.34091 1.295147453 0.33456 17.36191
36 37280_at MADH1  1.03448  1.06866713 1.033047673 0.48063 17.36191
37 33227_at IL10RB  1.017976  1.10172876 1.08227379 0.47487 17.36191
38 32529_at CKAP4  0.9990762  1.12343355 1.124472307 0.48333 17.36191
39 36312_at SERPINB8  0.9653125  1.26934824 1.31496097 0.47187 17.36191
40 1403_s_at CCL5  0.9613302  1.420866 1.478020843 0.30353 17.36191
Table 4 (Continued)
Order Probeset Gene ID Score (d) Numerator (r) Denominator (s+s0) Fold change q-value (%)
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Figure 4 FACS analysis of Herceptin staining of three primary OSPC and three USPC cell lines. Data with Herceptin are shown in solid black while
isotype control MAb profiles are shown in white. HER-2/neu expression was significantly higher on USPC cell lines compared to OSPC cell lines (Po0.001
by Student’s t-test).
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for these serous tumours and also provide insights into the
disproportionately poor prognosis of USPC relative to OSPC.
Consistent with this view, previous studies have reported that the
amplification of this gene in a subset of ovarian cancer patients is
associated with resistance to chemotherapeutic drugs and shorter
survival (Berchuck et al, 1990). On the light of our micrarrays data
it is tempting to speculate that some if not all of these highly
HER2/neu overexpressing and chemotherapy resistant serous
tumours may likely have arisen from metaplastic mesothelial cells
and therefore present a genetic fingerprint more similar to USPC
than OSPC. Regardless of the histologic site of origin, however,
high overexpression of the c-erbB2 gene provides support for the
notion that trastuzumab (Herceptin), a humanised anti-HER-2/
Neu antibody that is showing great promise for treatment of
metastatic breast cancer patients overexpressing HER-2/Neu
protein (Slamon et al, 2001), may be a novel, potentially highly
effective therapy against this aggressive variant of serous papillary
carcinomas. Consistent with this view, our group has recently
shown high sensitivity of USPC to the killing activity mediated by
natural killer (NK) cells when triggered by anti-HER-2/Neu-
specific antibody in vitro (Santin et al, 2002b).
Taken all together, our data demonstrate that OSPC and USPC,
two diseases where further molecular characterisation is needed to
improve differential diagnosis and therapeutic strategies, can be
readily discriminated solely by gene expression profiles. These
findings suggest that global gene expression signatures can be an
important adjunct to the morphology based classification schemes
for serous papillary tumours currently used. Finally, the identifica-
tion of c-erbB2 as the most highly differentially expressed gene in
USPC suggest that targeting HER-2/neu by rhuMAb anti-HER-2
(Herceptin) may be potentially highly beneficial against these
biologically aggressive and chemotherapy-resistant variants of
endometrial cancer.
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